جستجوی مقالات مرتبط با کلیدواژه "cholecalciferol" در نشریات گروه "پزشکی"

Helicobacter pylori (HPY) provokes gastrointestinal disorders and gastric cancer. We supposed that HPY disrupts the 25‑OH‑Vitamin‑D3 (Vit.D3) absorption. We evaluated the association between Vit.D3 and anti‑HPY immunoglobulins (Igs) and the Vit.D3 potency as a predictive biomarker for HPY infection.

603 patients’ raw data were gathered from a private clinical laboratory. Anti‑HPY Igs including serum IgG, IgA, and IgM, in addition to HPY‑stool antigen, were assessed by the immunoassay methods. Vit.D3 was determined by high‑pressure liquid chromatography. Correlations, ordinal comparisons, cutoff points (COP), and odds ratio (OR) were estimated.

The age mean ± standard deviation was 39.83 ± 18.426 for female and 38.82 ± 16.937 for male participants (P = 0.521). Significant correlations existed after age and gender adjustment between Vit.D3 serum levels and the HPY IgG (R = 0.298) and IgA (R = 0.271) but not for IgM (R = −0.103). Approximately, 48% of males and 36% of females had insufficient/deficient Vit.D3 serum levels(male/female OR: 1.65; 1.16–2.33; P= 0.0051). After age and gender adjustment, the best COP of Vit.D3 to predict an HPY IgG‑positive patient was Vit.D3 >32.80 ng/mL with 66.23% diagnostic accuracy (DAAC), 30.43% specificity (SPC), and 90.41% sensitivity (SEN). For the HPY IgA, the values were Vit. D3 >37.83 ng/mL, DAAC = 60.45%, SPC = 58.82%, SEN = 64.20%. For HPY IgM, the values were Vit.D3 >37.32 ng/mL, DAAC = 58.97%, SPC = 57.33%, and SEN = 100%.

Vit.D3 had a good association with anti‑HPY Igs and may be a good biomarker for immunity competence against HPY infection if the patient’s age and gender are considered when interpreting the laboratory results.

 Exercise and vitamin D can improve bone density by reducing bone loss. Growth factors such as IGF-I and IGFBP-3 are appeared to increase bone turnover in response to mechanical load, and free radicals attenuate the release of these growth factors.

 We assessed the effect of concurrent aerobic training and cholecalciferol administration along with hydrogen peroxide injection on the levels of IGF-I and IGFBP-3 expression in the bone tissue of rats.

 Thirty-six adult Wistar rats were randomized into six groups (n = 6), including healthy control, sham, hydrogen peroxide (H2O2), H2O2 + aerobic training, H2O2 + cholecalciferol, and H2O2 + aerobic training + cholecalciferol. The rats were intraperitoneally administered with one mmol/kg. Body weight (BW) of H2O2 three times a week on even days and 0.5 μg/kg.bw of cholecalciferol daily. Aerobic training (at a speed of 4 - 20 m/min, for 20 - 60 minutes) was performed five days/w for eight weeks. The expression of IGF-I and IGFBP-3 was measured by real-time (RT)-PCR. Data were analyzed using the independent t-test, two-way ANOVA (exercise × vitamin D), and Bonferroni’s post-hoc test in SPSS 26 at the significance level of P ≤ 0.05.

 The results showed that H2O2 significantly reduced the gene expressions of IGF-I (P = 0.001) and IGFBP-3 (P = 0.001) in the bone tissue. Also, exercise and vitamin D augmented the expression of IGF-I (P = 0.008) and IGFBP-3 (P = 0.0001) as post-hoc analysis showed that aerobic training had the greatest effect on the expression of IGF-I and IGFBP-3 (P < 0.05). In addition, the amplifying effects of aerobic training and cholecalciferol on the gene expressions of IGF-I and IGFBP-3 were also remarkable (P < 0.1).

 The mechanical load created by aerobic training exerted the greatest augmenting effect on the gene expression of IGF-I and IGFBP-3. Moreover, the interactive effect of aerobic training and cholecalciferol was also significant.

About 55% of extremely-low-birth-weight (birth weight < 1000 g) and 23% of very low-birth-weight infants (birth weight < 1500 g) suffer from metabolic bone disease (MBD). There are limited data on the use of calcitriol (1, 25-dihydroxycholecalciferol) to prevent or treat MBD in preterm infants. Therefore, this study aimed to compare the preventive effect of calcitriol and cholecalciferol on the biochemical markers of MBD in preterm infants.

This study was a pilot randomized controlled trial conducted in the Alzahra teaching hospital of Tabriz University of Medical Sciences. we randomized 72 very-low-birth-weight infants in two groups of calcitriol 0.25 μg/day and cholecalciferol 400 IU/day. Biochemical markers, including serum 25-hydroxyvitamin D, alkaline phosphatase (ALP), phosphorus (P),calcium (Ca), parathyroid hormone (PTH), and tubular reabsorption of phosphate (TRP) levels were checked at baseline, three, and five weeks after medication, consecutively.

After three weeks of supplementation, infants in the cholecalciferol group had higher levels of serum 25-hydroxyvitamin D (P=0.001) and lower levels of urine phosphate (P=0.009); There were no significant differences in other biochemical markers. At the end of the fifth week, there was no significant difference between the two groups in terms of biochemical markers.

The study indicated that the use of cholecalciferol caused a lower urinary loss of phosphate in very-low birth-weight infants at a short time; however, these findings were not sustained during the study period.

Depression is considered as a factor causing significant disability, mortality and healthcare costs and The third leading cause of disability which affects about 840 million people around the world. There are some biological, psychological and environmental theories explaining the pathophysiology of depression, though the main reason is still unknown. Vitamin D as a unique neurosteroid hormone may have an important role in the improvement of depression. Although the relationship between vitamin D levels and depressive symptoms has been explored, the results are inconsistent. Evidences about the relationship between vitamin D deficiency and depression are in conflict. Many studies indicted that, taking vitamin D supplements can be considered as a useful interventions for depressed patients with vitamins deficiency . The current review study suggests that, higher vitamin D intake may be associated with a lower prevalence of depressive symptoms. Neurons and glia in many parts of the brain such as the cingulate cortex and hippocampus have vitamin D receptors. There are different brain process which vitamin D involved including; Neuroimmunomodulation, regulation of neurotrophic factors, neuroprotection, neuroplasticity and brain development are kinds of brain processes. This fact demonstrates that vitamin D might be associated with depression and its supplementation might play an significant role in depression and its treatment .

Due to the fact that there is evidence indicating the role of Vitamin D in non-alcoholic fatty liver disease (NAFLD) as well as insulin resistance (IR) and adipokines production, studies examining Vitamin D on the metabolic factors involving NAFLD is required.

Therefore, we aimed to investigate the effect of single intramuscular injection of cholecalciferol on serum levels of Vitamin D, biochemical factors, and liver function status of women with NAFLD.

This randomized controlled clinical trial was conducted on 82 NAFLD patients with Vitamin D deficiency (< 30 ng/mL), who were selected through convenience sampling from October 2015 to March 2016 in Tabriz, Iran, and were randomly assigned into an intervention (a single intramuscular injection of 600,000 IU of cholecalciferol) or control group. Before and after the study, serum glucose, insulin, 25-hydroxy Vitamin D, adiponectin, liver enzymes, calcium, phosphors and parathyroid hormone (PTH), as well as homeostasis model assessment (HOMA-IR), body composition, dietary intake, and physical activity level were assessed.

After one month intervention, serum 25-hydroxyvitamin D significantly increased in the intervention group vs. the control (24.9 ± 17.4 vs. 9.1 ± 5.6, P = 0.003). Total body fat (TF) decreased in the intervention group (P = 0.001) while visceral fat (VF) was significantly different between the groups (P < 0.001). Adiponectin, calcium, phosphors, and PTH levels increased, while liver enzymes, insulin, and HOMA-IR decreased in both groups (P < 0.05). There were significant differences in mean changes of serum 25(OH) D, PTH, ALT, AST, ALP, and FBS between the groups after adjusting for baseline, TF and VF. Vitamin D injection did improve NAFLD severity (P = 0.01).

Cholecalciferol injection improved Vitamin D status and hepatic steatosis